Zobrazeno 1 - 10
of 231
pro vyhledávání: '"Huiqiang, Huang"'
Autor:
Changling Cao, Li Yuan, Yinfeng Wang, Haitao Liu, Haider Cuello Garcia, Huiqiang Huang, Weiqiang Tan, Yang Zhou, Haifeng Shi, Tingya Jiang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The donor-derived cell-free DNA (ddcfDNA) is found in the plasma and urine of kidney transplant recipients and displays notable potential in diagnosing rejection, specifically antibody-mediated rejection (ABMR). Nonetheless, the quantitative methods
Externí odkaz:
https://doaj.org/article/b7f2021ca25843cfa349373b366db35e
Autor:
Yan Gao, Haixia He, Xueping Li, Liling Zhang, Wei Xu, Ru Feng, Wenyu Li, Yin Xiao, Xinxiu Liu, Yu Chen, Xiaoxiao Wang, Bing Bai, Huijing Wu, Qingqing Cai, Zhiming Li, Jibin Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jiaying Mao, Xiujin Chen, Baitian Zhao, Huiqiang Huang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and the duration of response (DOR) need to be improved. This phase 1b/2
Externí odkaz:
https://doaj.org/article/583932d69bc54c3c805fc537107b6589
Autor:
Ning Su, Yu Fang, Xu Chen, Xiaoqin Chen, Zhongjun Xia, Huiqiang Huang, Yi Xia, Panpan Liu, Xiaopeng Tian, Qingqing Cai
Publikováno v:
Blood Science, Vol 5, Iss 4, Pp 249-257 (2023)
T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive non-Hodgkin lymphoma with a poor prognosis. P21-activated kinase (PAK) is a component of the gene expression-based classifier that can predict the prognosis of T-LBL. However, the role of P
Externí odkaz:
https://doaj.org/article/b29c8fc267084295bc056f72b7b09f61
Autor:
Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen, Jun Ma, Cheng-Shyong Chang, Eric Wai Choi Tse
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-26 (2023)
Abstract Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good cl
Externí odkaz:
https://doaj.org/article/910b3c2480ed4cd4b9096ea9dadac833
Autor:
Jinghong Chen, Zhixiang Zuo, Yan Gao, Xiaosai Yao, Peiyong Guan, Yali Wang, Zhimei Li, Zhilong Liu, Jing Han Hong, Peng Deng, Jason Yongsheng Chan, Daryl Ming Zhe Cheah, Jingquan Lim, Kelila Xin Ye Chai, Burton Kuan Hui Chia, Jane Wan Lu Pang, Joanna Koh, Dachuan Huang, Haixia He, Yichen Sun, Lizhen Liu, Shini Liu, Yuhua Huang, Xiaoxiao Wang, Hua You, Sahil Ajit Saraf, Nicholas Francis Grigoropoulos, Xiaoqiu Li, Jinxin Bei, Tiebang Kang, Soon Thye Lim, Bin Tean Teh, Huiqiang Huang, Choon Kiat Ong, Jing Tan
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-16 (2023)
Abstract Background Natural killer/T-cell lymphoma (NKTL) is a rare type of aggressive and heterogeneous non-Hodgkin's lymphoma (NHL) with a poor prognosis and limited therapeutic options. Therefore, there is an urgent need to exploit potential novel
Externí odkaz:
https://doaj.org/article/63014556270748ed98fa1bb18898c8a1
Autor:
Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan Hodkinson, Sriram Balasubramanian, Songbai Wang, Qingyuan Zhang, Yuankai Shi, Huiqiang Huang, Huilai Zhang, Yan Zhu, Stephen Martin Shreeve, Steven Sun, Ze Wang, Xiaocan Wang, Yue Fan, Wyndham Wilson, Jessica Vermeulen
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1154-1164 (2022)
Abstract In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did no
Externí odkaz:
https://doaj.org/article/c5c60059677a4edd904790870a35470b
Autor:
Yuchen Zhang, Panpan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhiming Li, He Huang, Yi Xia, Qingqing Cai
Publikováno v:
Cancer Medicine, Vol 11, Iss 22, Pp 4134-4145 (2022)
Abstract Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real
Externí odkaz:
https://doaj.org/article/436b7378b4a54994a94a31e6fd1a8a22
Autor:
Xiaoqing Chen, Yunwei Hu, Wenru Su, Shizhao Yang, Xiaoxiao Wang, Ping Zhang, Xiaoyu Hong, Chuqiao Liang, Zhuyun Qian, Ziqiang Li, Yong Tao, Huiqiang Huang, Dan Liang
Publikováno v:
Cancer Communications, Vol 42, Iss 11, Pp 1217-1221 (2022)
Externí odkaz:
https://doaj.org/article/82f167911d464cd3904044b688be5bf0
Autor:
Qingqing Cai, Weili Zhao, Liang Wang, Zhihua LI, Hanguo Guo, Jinni Wang, Jie Xiong, Huiqiang Huang, Yi Xia
Publikováno v:
HemaSphere, Vol 7, p e60202e5 (2023)
Externí odkaz:
https://doaj.org/article/5e1b0595176d47b1a2a65d841a5a01b5
Autor:
Huilai Zhang, Ying Cheng, Hai-Yan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Zhiyu Liang, Jiaoyan Lyu, Yiqian Fang, Aileen Cohen, Keshu Zhou
Publikováno v:
HemaSphere, Vol 7, p e1828304 (2023)
Externí odkaz:
https://doaj.org/article/e3ab17b2c346479f98c610d21d8a14e0